000281823 001__ 281823
000281823 005__ 20251113121746.0
000281823 0247_ $$2doi$$a10.1007/s12035-025-05252-2
000281823 0247_ $$2pmid$$apmid:40758158
000281823 0247_ $$2ISSN$$a0893-7648
000281823 0247_ $$2ISSN$$a1559-1182
000281823 037__ $$aDZNE-2025-01204
000281823 041__ $$aEnglish
000281823 082__ $$a570
000281823 1001_ $$00000-0001-9557-9243$$aDemleitner, Antonia F$$b0
000281823 245__ $$aAn Exploratory Analysis of Differential Tear Fluid miRNAs in Patients with Parkinson's Disease and Atypical Parkinsonian Syndromes.
000281823 260__ $$aTotowa, NJ$$bHumana Press$$c2025
000281823 3367_ $$2DRIVER$$aarticle
000281823 3367_ $$2DataCite$$aOutput Types/Journal article
000281823 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1763032439_32675
000281823 3367_ $$2BibTeX$$aARTICLE
000281823 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000281823 3367_ $$00$$2EndNote$$aJournal Article
000281823 520__ $$aParkinson's disease (PD), multiple system atrophy (MSA), and progressive supranuclear palsy (PSP) are neurodegenerative disorders diagnosed by clinical criteria with limited diagnostic specificity in early stages. Diagnostic biomarkers facilitating early and precise diagnosis are needed. Tear fluid (TF) is an easily accessible body fluid reflecting pathophysiological changes in ocular and systemic diseases. In this exploratory study, we investigate TF as a non-invasive source of disease-specific miRNAs for PD, MSA, and PSP. We demonstrate reduced TF production in PD patients. Using a real-time quantitative PCR-based array targeting 1113 miRNAs, we identified 55 exclusively expressed in PD, 35 in PSP, and 14 in MSA, respectively. Several of these have previously been identified in other biofluids. Overrepresentation analysis of target genes showed apoptotic and cell differentiation pathways as common targets. While these findings suggest that miRNA alterations in TF might reflect disease mechanisms in PD and atypical Parkinsonian syndromes, the exploratory character of the study combined with the use of pooled samples, indicates the need for further validation. The small sample size highlights the importance of follow-up studies with larger, more definitive cohorts to confirm the potential of these miRNAs as reliable biomarkers.
000281823 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000281823 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000281823 650_7 $$2Other$$aAtypical Parkinsonian syndrome
000281823 650_7 $$2Other$$aBiomarker
000281823 650_7 $$2Other$$aMiRNA
000281823 650_7 $$2Other$$aMultiple system atrophy
000281823 650_7 $$2Other$$aProgressive supranuclear palsy
000281823 650_7 $$2Other$$aTear fluid
000281823 650_7 $$2NLM Chemicals$$aMicroRNAs
000281823 650_7 $$2NLM Chemicals$$aBiomarkers
000281823 650_2 $$2MeSH$$aHumans
000281823 650_2 $$2MeSH$$aMicroRNAs: metabolism
000281823 650_2 $$2MeSH$$aMicroRNAs: genetics
000281823 650_2 $$2MeSH$$aParkinson Disease: genetics
000281823 650_2 $$2MeSH$$aParkinson Disease: metabolism
000281823 650_2 $$2MeSH$$aMale
000281823 650_2 $$2MeSH$$aFemale
000281823 650_2 $$2MeSH$$aAged
000281823 650_2 $$2MeSH$$aTears: metabolism
000281823 650_2 $$2MeSH$$aMiddle Aged
000281823 650_2 $$2MeSH$$aMultiple System Atrophy: genetics
000281823 650_2 $$2MeSH$$aParkinsonian Disorders: genetics
000281823 650_2 $$2MeSH$$aParkinsonian Disorders: metabolism
000281823 650_2 $$2MeSH$$aSupranuclear Palsy, Progressive: genetics
000281823 650_2 $$2MeSH$$aBiomarkers: metabolism
000281823 7001_ $$00000-0003-4959-2169$$aGomes, Lucas Caldi$$b1
000281823 7001_ $$aWenz, Lara$$b2
000281823 7001_ $$00009-0003-7643-3232$$aTzeplaeff, Laura$$b3
000281823 7001_ $$00000-0003-4880-6575$$aPürner, Dominik$$b4
000281823 7001_ $$aLuib, Elena$$b5
000281823 7001_ $$0P:(DE-2719)9002311$$aKunze, Lea$$b6$$udzne
000281823 7001_ $$0P:(DE-2719)2812561$$aLingor, Paul$$b7$$eLast author
000281823 773__ $$0PERI:(DE-600)2079384-4$$a10.1007/s12035-025-05252-2$$gVol. 62, no. 12, p. 16397 - 16409$$n12$$p16397 - 16409$$tMolecular neurobiology$$v62$$x0893-7648$$y2025
000281823 8564_ $$uhttps://pub.dzne.de/record/281823/files/DZNE-2025-01204%20SUP1.docx
000281823 8564_ $$uhttps://pub.dzne.de/record/281823/files/DZNE-2025-01204%20SUP2.xls
000281823 8564_ $$uhttps://pub.dzne.de/record/281823/files/DZNE-2025-01204.pdf$$yOpenAccess
000281823 8564_ $$uhttps://pub.dzne.de/record/281823/files/DZNE-2025-01204%20SUP1.doc
000281823 8564_ $$uhttps://pub.dzne.de/record/281823/files/DZNE-2025-01204%20SUP1.odt
000281823 8564_ $$uhttps://pub.dzne.de/record/281823/files/DZNE-2025-01204%20SUP1.pdf
000281823 8564_ $$uhttps://pub.dzne.de/record/281823/files/DZNE-2025-01204%20SUP2.csv
000281823 8564_ $$uhttps://pub.dzne.de/record/281823/files/DZNE-2025-01204%20SUP2.ods
000281823 8564_ $$uhttps://pub.dzne.de/record/281823/files/DZNE-2025-01204.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000281823 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9002311$$aExternal Institute$$b6$$kExtern
000281823 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812561$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000281823 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000281823 9141_ $$y2025
000281823 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-07
000281823 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-07
000281823 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-01-07
000281823 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-01-07
000281823 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000281823 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMOL NEUROBIOL : 2022$$d2025-01-07
000281823 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-07
000281823 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2025-01-07$$wger
000281823 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-07
000281823 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000281823 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bMOL NEUROBIOL : 2022$$d2025-01-07
000281823 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-07
000281823 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-07
000281823 9201_ $$0I:(DE-2719)1111015$$kClinical Research (Munich)$$lClinical Research (Munich)$$x0
000281823 980__ $$ajournal
000281823 980__ $$aVDB
000281823 980__ $$aUNRESTRICTED
000281823 980__ $$aI:(DE-2719)1111015
000281823 9801_ $$aFullTexts